Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone502-241-4114
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees87
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Apellis Pharmaceuticals (NASDAQ:APLS) Frequently Asked Questions
What is Apellis Pharmaceuticals' stock symbol?
Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."
How were Apellis Pharmaceuticals' earnings last quarter?
Apellis Pharmaceuticals Inc (NASDAQ:APLS) announced its quarterly earnings data on Wednesday, July, 31st. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.80) by $0.18. View Apellis Pharmaceuticals' Earnings History.
When is Apellis Pharmaceuticals' next earnings date?
What price target have analysts set for APLS?
7 equities research analysts have issued 12-month price targets for Apellis Pharmaceuticals' stock. Their predictions range from $40.00 to $52.00. On average, they anticipate Apellis Pharmaceuticals' stock price to reach $45.1429 in the next year. This suggests a possible upside of 76.5% from the stock's current price. View Analyst Price Targets for Apellis Pharmaceuticals.
What is the consensus analysts' recommendation for Apellis Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Apellis Pharmaceuticals.
What are Wall Street analysts saying about Apellis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Apellis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States. " (7/16/2019)
- 2. Cantor Fitzgerald analysts commented, ": We are reiterating our OW rating on Apellis and lowering our 12-month price target to $52 from $57. This morning, Apellis issued a press release highlighting financial and corporate updates for the period ended on 3/31. Our decrease in price target is based off an increased share count, due to the recent March 2019 financing, and an increase to R&D and SG&A projections. With Phase 3 PEGASUS (PNH) enrollment expected to complete by the end of 2Q19, we believe APLS shares represent a strong buying opportunity, ahead of a potential 4Q19 data readout. Below we revisit our thoughts on APL-2 and its potential to be a disruptive addition to the PNH market." (5/8/2019)
Has Apellis Pharmaceuticals been receiving favorable news coverage?
News headlines about APLS stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Apellis Pharmaceuticals earned a news impact score of -2.9 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Apellis Pharmaceuticals.
Are investors shorting Apellis Pharmaceuticals?
Apellis Pharmaceuticals saw a increase in short interest in August. As of August 31st, there was short interest totalling 2,788,000 shares, an increase of 16.3% from the July 31st total of 2,398,100 shares. Based on an average daily trading volume, of 387,500 shares, the short-interest ratio is presently 7.2 days. Currently, 6.0% of the company's stock are short sold. View Apellis Pharmaceuticals' Current Options Chain.
Who are some of Apellis Pharmaceuticals' key competitors?
Some companies that are related to Apellis Pharmaceuticals include Dr.Reddy's Laboratories (RDY), Beigene (BGNE), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Amarin (AMRN), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), The Medicines (MDCO), United Therapeutics (UTHR), FibroGen (FGEN), Mirati Therapeutics (MRTX), Nektar Therapeutics (NKTR) and Allakos (ALLK).
What other stocks do shareholders of Apellis Pharmaceuticals own?
Who are Apellis Pharmaceuticals' key executives?
Apellis Pharmaceuticals' management team includes the folowing people:
- Dr. Cedric Francois, Co-Founder, Pres, CEO & Director (Age 47)
- Dr. Pascal Deschatelets, Co-Founder & COO (Age 49)
- Mr. Timothy E. Sullivan, Chief Financial Officer (Age 48)
- Dr. Federico Grossi M.D., Ph.D., Co-Founder and Exec. VP of Clinical Devel. & Medical Affairs (Age 45)
- Mr. Ahmad Sadr, VP of Technical Operations
When did Apellis Pharmaceuticals IPO?
(APLS) raised $150 million in an IPO on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.
Who are Apellis Pharmaceuticals' major shareholders?
Apellis Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.07%), Cormorant Asset Management LP (4.66%), Vanguard Group Inc. (3.22%), Victory Capital Management Inc. (2.61%), Jennison Associates LLC (1.45%) and Jennison Associates LLC (1.45%). Company insiders that own Apellis Pharmaceuticals stock include Cedric Francois, David O Watson, Global Strategic Fund I Venbio, Lukas Scheibler, Morningside Venture Investment and Timothy Eugene Sullivan. View Institutional Ownership Trends for Apellis Pharmaceuticals.
Which institutional investors are selling Apellis Pharmaceuticals stock?
APLS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Cormorant Asset Management LP, Westfield Capital Management Co. LP, Citadel Advisors LLC, Fosun International Ltd, Victory Capital Management Inc., Prudential Financial Inc. and Royal Bank of Canada. View Insider Buying and Selling for Apellis Pharmaceuticals.
Which institutional investors are buying Apellis Pharmaceuticals stock?
APLS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Jennison Associates LLC, Jennison Associates LLC, Nuveen Asset Management LLC, DekaBank Deutsche Girozentrale, Point72 Asset Management L.P., Pictet Asset Management Ltd. and Pictet Asset Management Ltd.. Company insiders that have bought Apellis Pharmaceuticals stock in the last two years include Global Strategic Fund I Venbio, Lukas Scheibler, Morningside Venture Investment and Timothy Eugene Sullivan. View Insider Buying and Selling for Apellis Pharmaceuticals.
How do I buy shares of Apellis Pharmaceuticals?
Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Apellis Pharmaceuticals' stock price today?
One share of APLS stock can currently be purchased for approximately $25.57.
How big of a company is Apellis Pharmaceuticals?
Apellis Pharmaceuticals has a market capitalization of $1.63 billion. The company earns $-127,500,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. Apellis Pharmaceuticals employs 87 workers across the globe.View Additional Information About Apellis Pharmaceuticals.
What is Apellis Pharmaceuticals' official website?
How can I contact Apellis Pharmaceuticals?
Apellis Pharmaceuticals' mailing address is 6400 WESTWIND WAY SUITE A, CRESTWOOD KY, 40014. The company can be reached via phone at 502-241-4114 or via email at [email protected]
MarketBeat Community Rating for Apellis Pharmaceuticals (NASDAQ APLS)
MarketBeat's community ratings are surveys of what our community members think about Apellis Pharmaceuticals and other stocks. Vote "Outperform" if you believe APLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
